# Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

> **NCT06495918** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 825 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** OTX-TKI
- **DRUG:** Aflibercept
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT06495918
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-01-08
- **Target enrollment:** 825 (ESTIMATED)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495918, "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06495918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*